Alsuma (autoinjector) is a drug owned by Meridian Medical Technologies Inc Sub King Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 26, 2027. Details of Alsuma (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7811254 | Autoinjector with needle depth adapter |
Aug, 2027
(10 months from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Alsuma (autoinjector) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Alsuma (autoinjector)'s family patents as well as insights into
ongoing legal events
on those patents.
Alsuma (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alsuma (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 26, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alsuma (autoinjector) Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Alsuma (autoinjector). 31 different companies have already filed for the generic of Alsuma (autoinjector), with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Alsuma (autoinjector)'s generic
Alternative Brands for Alsuma (autoinjector)
There are several other brand drugs using the same active ingredient (Sumatriptan Succinate) as Alsuma (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Endo Operations |
| ||
| Teva Branded Pharm |
| ||
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Alsuma (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Alsuma (autoinjector)
About Alsuma (autoinjector)
Alsuma (Autoinjector) is a drug owned by Meridian Medical Technologies Inc Sub King Pharmaceuticals Inc. Alsuma (Autoinjector) uses Sumatriptan Succinate as an active ingredient. Alsuma (Autoinjector) was launched by Meridian Medcl in 2010.
Approval Date:
Alsuma (autoinjector) was approved by FDA for market use on 29 June, 2010.
Active Ingredient:
Alsuma (autoinjector) uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Dosage:
Alsuma (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | SOLUTION | Discontinued | SUBCUTANEOUS |